CNTRP research selected as the CRCHUM Discovery of the year: the potential to revolutionize transpla
Drs. Marie-Josée Hébert and Mélanie Dieudé, CNTRP Project 3 Leads, and their teams discovered a new membrane vesicle cell structure responsible for previously unexplained rejections following a solid organ transplant. They also identified that a common transplant drug, Bortezomib, is capable of preventing this type of rejection. This groundbreaking research could one day revolutionize transplant practice and we will continue to explore this discovery within the CNTRP. Our CNTRP Core 4 Co-Lead, Sylvain Bédard, explains in the video the impact that this discovery can have on his own transplant.
The CNTRP is very proud of Drs Hébert and Dieudé on being named the recipients of the CRCHUM Award of Excellence in Research - Science Contribution of 2016.
Dieudé M, Bell C, Turgeon J, Beillevaire D, Pomerleau L, Yang, B, Hamelin K, Qi S, Pallet N, Béland C, Dhahri W, Cailhier JF, Rousseau M, Duchez AC, Lévesque T, Lau A, Rondeau C, Gingras D, Muruve D, Rivard A, Cardinal H, Perreault C, Desjardins M, Boilard E, Thibault P, Hébert MJ. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med. Dec 16;7(318):318ra200, 2015